Cystatin C: Evidence-Based Ways to Improve This Number

What Is Cystatin C and Why Does It Matter?

Cystatin C is a small protein produced at a near-constant rate by all nucleated cells in the body. The kidneys filter it freely at the glomerulus, then reabsorb and break it down in the tubules, so almost none returns to the bloodstream. A rising serum level signals that the glomerular filtration rate (GFR) is falling.

Unlike serum creatinine, cystatin C is not heavily influenced by skeletal muscle mass. That distinction matters. Creatinine-based eGFR can overestimate kidney function in older adults, women, and people with low muscle mass, and underestimate it in bodybuilders or patients on high-protein diets. A 2012 meta-analysis of 11 general-population cohorts (N = 90,750) published in the New England Journal of Medicine found that adding cystatin C to creatinine reclassified 19.4% of participants into a different CKD stage compared with creatinine alone, and the combined equation more accurately predicted kidney failure and mortality 1.

The 2024 KDIGO guidelines for Chronic Kidney Disease evaluation and management explicitly recommend using cystatin C-based or combined creatinine-cystatin C equations "when confirmation of eGFR based on creatinine is needed" 2. The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) 2021 equations, which removed race as a variable, incorporate cystatin C as the preferred confirmatory biomarker.

Your cystatin C value, then, is not just a lab curiosity. It is a direct window into how well your kidneys are filtering blood. Improving it means improving filtration.

Normal Cystatin C Ranges

Most clinical laboratories report a reference interval of 0.62 to 1.15 mg/L for healthy adults. Values above 1.15 mg/L typically correspond to reduced GFR. The exact cutpoints vary slightly by assay manufacturer, but the International Federation of Clinical Chemistry (IFCC) has standardized calibration to a certified reference material (ERM-DA471/IFCC) since 2010 3.

What shifts cystatin C outside the normal range? Kidney disease is the primary driver. But several non-renal factors can nudge levels. High-dose corticosteroids increase cystatin C production independent of GFR. Untreated hyperthyroidism raises it. Obesity is associated with mildly elevated cystatin C, likely through low-grade inflammation rather than reduced filtration alone 4. These confounders are fewer and smaller in magnitude than those affecting creatinine, which is why cystatin C remains the preferred confirmatory marker.

If your level sits between 1.0 and 1.15 mg/L, you are in a gray zone. Repeating the test in three to six months while addressing modifiable risk factors is reasonable. A level above 1.3 mg/L warrants a nephrology referral in most clinical contexts.

Blood Pressure Control: The Strongest Modifiable Risk Factor

Sustained hypertension damages the glomerular capillaries that determine your cystatin C level. Bringing systolic blood pressure below 120 mmHg provided a measurable kidney benefit in the SPRINT trial. Among 9,361 participants with hypertension (but without diabetes), intensive blood pressure control (target systolic <120 mmHg) reduced the composite kidney outcome by 15% compared to standard control (target <140 mmHg) over 3.3 years of median follow-up 5.

First-line agents for kidney protection include ACE inhibitors and angiotensin receptor blockers (ARBs). The REIN trial demonstrated that ramipril reduced proteinuria and the rate of GFR decline in patients with non-diabetic nephropathy 6. Dr. George Bakris, professor of medicine at the University of Chicago and a co-author of the 2024 KDIGO blood pressure guidelines, has stated: "RAS blockade remains the backbone of kidney-protective antihypertensive therapy, and its benefit is proportional to the degree of proteinuria at baseline."

Practical application: if your cystatin C is trending upward, have your blood pressure checked at home (not just in-office) and discuss ACE inhibitor or ARB therapy with your clinician if systolic readings exceed 130 mmHg on repeated measurement.

SGLT2 Inhibitors: The Largest Kidney-Specific Pharmacologic Benefit

Sodium-glucose cotransporter-2 (SGLT2) inhibitors were developed as glucose-lowering drugs, but their kidney-protective effects have become their most consequential clinical contribution. These agents reduce intraglomerular pressure by restoring tubuloglomerular feedback at the macula densa.

DAPA-CKD (N = 4,304) randomized patients with CKD and eGFR 25 to 75 mL/min/1.73 m² to dapagliflozin 10 mg or placebo. Dapagliflozin reduced the composite endpoint of sustained eGFR decline of 50% or more, end-stage kidney disease, or renal death by 39% (HR 0.61, 95% CI 0.51 to 0.72, P <0.001) 7. The benefit appeared regardless of whether patients had diabetes.

EMPA-KIDNEY (N = 6,609) confirmed the class effect with empagliflozin. Kidney disease progression or cardiovascular death fell by 28% (HR 0.72, 95% CI 0.64 to 0.82) 8. Patients with eGFR as low as 20 mL/min/1.73 m² were included, broadening the applicable population.

An expected feature of SGLT2 inhibitor therapy is an initial "hemodynamic dip" in eGFR of 3 to 5 mL/min/1.73 m² within the first two to four weeks. This reflects reduced intraglomerular pressure, not kidney injury. Cystatin C-based eGFR will drop slightly at first. The dip reverses over time, and the long-term trajectory is a slower rate of GFR decline compared to placebo. Clinicians should not discontinue the drug because of this early signal.

GLP-1 Receptor Agonists: Kidney Protection Beyond Weight Loss

GLP-1 receptor agonists (GLP-1 RAs) reduce inflammation, lower blood pressure, and improve glycemic control. All of these effects benefit the kidneys. But the FLOW trial provided the first dedicated kidney outcome data for the class.

FLOW (N = 3,533) randomized adults with type 2 diabetes and CKD (eGFR 25 to 75 mL/min/1.73 m²) to subcutaneous semaglutide 1.0 mg weekly or placebo. Semaglutide reduced the primary composite kidney endpoint (sustained eGFR decline of 50% or more, kidney failure, kidney death, or cardiovascular death) by 24% (HR 0.76, 95% CI 0.66 to 0.88) 9. The trial was stopped early for efficacy after a median follow-up of 3.4 years.

The 2024 KDIGO guidelines now list GLP-1 RAs as a recommended therapy for patients with type 2 diabetes and CKD who do not reach glycemic targets on metformin and SGLT2 inhibitors, or who need additional cardiorenal protection 2.

For patients already taking semaglutide or tirzepatide for weight management, the kidney benefit is a meaningful secondary advantage worth tracking through cystatin C trends.

Glycemic Control in Diabetes

Hyperglycemia drives glomerular hyperfiltration, mesangial expansion, and eventual nephron loss. Tight glycemic management slows that process. The ADVANCE trial (N = 11,140) showed that intensive glucose control (target HbA1c <6.5%) reduced new or worsening nephropathy by 21% compared to standard care over 5 years in type 2 diabetes 10.

Metformin remains the first-line oral agent for type 2 diabetes and is now considered safe at eGFR levels down to 30 mL/min/1.73 m² per updated FDA labeling 11. Below that threshold, dose reduction or discontinuation is warranted.

The ADA Standards of Care (2024) recommend an HbA1c target of <7% for most adults with diabetes, individualized to <6.5% in those at low hypoglycemia risk and <8% in those with advanced complications or limited life expectancy 12.

For cystatin C specifically: achieving stable glycemic control prevents the hyperfiltration phase (which can mask early kidney damage behind a falsely normal cystatin C) and reduces the progression to overt nephropathy.

Dietary Strategies

High dietary protein intake increases renal blood flow and intraglomerular pressure. In patients with existing CKD (stages 3 to 5), moderate protein restriction (0.6 to 0.8 g/kg/day) slows the rate of GFR decline. A Cochrane systematic review of 17 trials (N = 2,996) confirmed that low-protein diets reduced the risk of reaching kidney failure by 32% compared to unrestricted protein intake in non-diabetic CKD 13.

Sodium restriction matters as well. Dietary sodium above 4 g/day blunts the antiproteinuric effect of ACE inhibitors and ARBs. The DASH diet (rich in fruits, vegetables, whole grains, and low-fat dairy while limiting sodium to 2.3 g/day) was associated with a 16% lower incidence of CKD over 23 years of follow-up in the ARIC cohort study 14.

Key dietary targets for kidney protection:

• Protein: 0.8 g/kg/day if eGFR is <60 mL/min/1.73 m²; no strict restriction needed above that threshold
• Sodium: <2.3 g/day (about one teaspoon of table salt)
• Potassium: adequate intake through whole foods unless serum potassium is already elevated
• Ultra-processed food: minimize, as it is the leading source of hidden sodium and phosphate additives

Exercise and Body Composition

Aerobic exercise improves endothelial function, lowers blood pressure, and reduces systemic inflammation, all of which protect glomerular filtration. Data from the Atherosclerosis Risk in Communities (ARIC) study showed that participants meeting physical activity guidelines (150 min/week of moderate exercise) had a 1.5 to 2.0 mL/min/1.73 m² higher eGFR over a decade compared to sedentary participants 15.

A 2019 meta-analysis of 12 RCTs in CKD patients found that structured aerobic exercise programs improved eGFR by a mean of 2.16 mL/min/1.73 m² (95% CI 0.42 to 3.90) and reduced systolic blood pressure by 4.3 mmHg compared to usual care 16.

Obesity itself raises cystatin C independently of GFR. Visceral adiposity increases production of inflammatory cytokines (TNF-alpha, IL-6) that upregulate cystatin C gene expression. Weight loss of 5% to 10% of body weight through caloric deficit and exercise can reduce cystatin C by 0.03 to 0.07 mg/L independent of changes in true GFR 4. This is a confounder worth understanding: if your cystatin C drops after weight loss, part of the improvement reflects reduced adipose-driven production rather than improved filtration. Both effects are beneficial, but your clinician may recheck the value after weight stabilizes.

Medications and Supplements to Use with Caution

Several commonly used drugs can raise cystatin C through direct nephrotoxicity or hemodynamic effects. Nonsteroidal anti-inflammatory drugs (NSAIDs) reduce renal blood flow by inhibiting prostaglandin synthesis. Regular NSAID use for more than 30 days was associated with a 32% increased risk of incident CKD in a cohort of 10,184 community-dwelling adults 17.

Proton pump inhibitors (PPIs) taken for longer than one year have been associated with a 20% to 50% increased risk of CKD in observational studies, though residual confounding cannot be excluded 18.

The American College of Physicians recommends: "Clinicians should avoid prescribing NSAIDs in patients with existing CKD and should limit PPI use to the shortest effective duration" 19.

As for supplements marketed as "kidney support" (astragalus, cordyceps, alpha-lipoic acid), no randomized trial has demonstrated a clinically meaningful improvement in cystatin C or eGFR. Patients should not substitute unproven supplements for evidence-based pharmacotherapy.

Treating Underlying Conditions That Raise Cystatin C

Because cystatin C reflects GFR, any condition that damages nephrons will raise it. The most common causes are:

• Diabetic kidney disease: addressed through glycemic control, SGLT2 inhibitors, GLP-1 RAs, and finerenone (a nonsteroidal mineralocorticoid receptor antagonist that reduced CKD progression by 23% in the FIDELIO-DKD trial, N = 5,734) 20
• Hypertensive nephrosclerosis: addressed through blood pressure control with RAS blockade
• Glomerulonephritis: may require immunosuppressive therapy guided by kidney biopsy
• Obstructive uropathy: requires urologic evaluation and intervention

Non-renal confounders to rule out before attributing a high cystatin C to kidney disease: uncontrolled hyperthyroidism (thyroid hormone increases cystatin C gene expression), high-dose systemic corticosteroids, and active malignancy. A simple TSH check can eliminate the thyroid confounder.

How Often to Recheck Cystatin C

The frequency depends on your baseline. For a normal cystatin C (<1.0 mg/L) with no risk factors, annual or biennial screening is reasonable if you are over age 50 or have hypertension, diabetes, or a family history of kidney disease. For values between 1.0 and 1.3 mg/L, repeat in three to six months while addressing modifiable risk factors. For values above 1.3 mg/L, nephrology referral and serial monitoring every three months is standard practice per KDIGO staging guidelines 2.

Pair cystatin C with a urine albumin-to-creatinine ratio (UACR) at every check. KDIGO defines CKD by both GFR and albuminuria; tracking one without the other gives an incomplete picture. A UACR above 30 mg/g signals kidney damage even when eGFR is still normal.

The combination of a falling cystatin C-based eGFR and a rising UACR is the earliest detectable signal that kidney function is deteriorating, often years before symptoms appear.